Lincoln Pharmaceuticals Reports Rs 11.63 Crore Profit in Fiscal Quarter Four

Lincoln Pharmaceuticals Reports Marginal Increase in Profit

Lincoln Pharmaceuticals, a healthcare company, reported a marginal increase in profit at Rs 11.63 crore in the fourth quarter ended March 31, 2026. This marks a slight improvement from the same period of the previous year, when the company posted a profit of Rs 11.57 crore.

The company's revenue from operations saw a notable increase, rising by 13.5 per cent to Rs 183.08 crore in the quarter under review. This is compared to Rs 161.30 crore reported in the last quarter of FY25.

Financial Highlights for FY26

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

For the full 2025-26 fiscal, Lincoln Pharma reported over 6 per cent growth in consolidated net profit to Rs 87.89 crore compared to the net profit of Rs 82.35 crore in FY25. Revenue from operations for FY26 was reported at Rs 704.48 crore, marking a growth of 9.10 per cent year-over-year.

The company's board has recommended a dividend of 18 per cent, Rs 1.80 per share on the face value of Rs 10 per share for the FY 2025-26. Looking ahead, Lincoln Pharmaceuticals is targeting a revenue of Rs 1,000 crore within the next three years, driven by business expansion into high-value product lines and entry into new markets.